Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Tandem Diabetes Care, Inc. before investing.

In this article, we go over a few key elements for understanding Tandem Diabetes Care, Inc.’s stock price such as:

• Tandem Diabetes Care, Inc.’s current stock price and volume
• Why Tandem Diabetes Care, Inc.’s stock price changed recently
• Upgrades and downgrades for TNDM from analysts
• TNDM’s stock price momentum as measured by its relative strength

About Tandem Diabetes Care, Inc. (TNDM)

Before we jump into Tandem Diabetes Care, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company’s flagship product is the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user’s body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Want to learn more about Tandem Diabetes Care, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Tandem Diabetes Care, Inc..

Tandem Diabetes Care, Inc.’s Stock Price as of Market Close

As of November 28, 2025, 1:00 PM, CST, Tandem Diabetes Care, Inc.’s stock price was $21.010.

Tandem Diabetes Care, Inc. is up 1.35% from its previous closing price of $20.730.

During the last market session, Tandem Diabetes Care, Inc.’s stock traded between $20.243 and $21.170. Currently, there are approximately 67.65 million shares outstanding for Tandem Diabetes Care, Inc..

Tandem Diabetes Care, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Tandem Diabetes Care, Inc. Stock Price History

Tandem Diabetes Care, Inc.’s (TNDM) price is currently up 50.07% so far this month.

During the month of November, Tandem Diabetes Care, Inc.’s stock price has reached a high of $22.130 and a low of $13.235.

Over the last year, Tandem Diabetes Care, Inc. has hit prices as high as $38.280 and as low as $9.980. Year to date, Tandem Diabetes Care, Inc.’s stock is down 41.67%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Tandem Diabetes Care, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 28, 2025, there were 2 analysts who downgraded Tandem Diabetes Care, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Tandem Diabetes Care, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Tandem Diabetes Care, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Tandem Diabetes Care, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Tandem Diabetes Care, Inc. (TNDM) by visiting AAII Stock Evaluator.

Relative Price Strength of Tandem Diabetes Care, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 28, 2025, Tandem Diabetes Care, Inc. has a weighted four-quarter relative price strength of 6.71%, which translates to a Momentum Score of 77 and is considered to be Strong.

Want to learn more about how Tandem Diabetes Care, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Tandem Diabetes Care, Inc. Stock Price: Bottom Line

As of November 28, 2025, Tandem Diabetes Care, Inc.’s stock price is $21.010, which is up 1.35% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Tandem Diabetes Care, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.